Clinical Trial Update: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS [Phase 3]

View source ↗

Summary

Phase 3 trial investigating oral levosimendan (ODM-109) for respiratory function in amyotrophic lateral sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Levosimendan (levosimendan)
• ODM-109

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2021-08-31